Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-03-01
2005-03-01
Harris, Alana M. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C536S001001, C536S018700, C536S022100, C536S023100, C536S023500, C514S001000, C514S002600, C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300, C424S009100, C424S009200
Reexamination Certificate
active
06861506
ABSTRACT:
Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by such nucleotide sequences. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer in a patient.
REFERENCES:
patent: 5231012 (1993-07-01), Mosmann et al.
patent: 5428145 (1995-06-01), Okamoto et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5523225 (1996-06-01), Kraus
patent: 5585270 (1996-12-01), Grotendorst et al.
patent: 5811535 (1998-09-01), Adamou et al.
patent: 5872237 (1999-02-01), Feder et al.
patent: 6329505 (2001-12-01), Xu et al.
patent: 2044940 (1992-12-01), None
patent: 0475623 (1992-03-01), None
patent: 2 273 099 (1994-06-01), None
patent: WO 9102062 (1991-02-01), None
patent: WO 9210573 (1992-06-01), None
patent: WO 9215680 (1992-09-01), None
patent: WO 9811514 (1994-05-01), None
patent: WO 9510777 (1995-04-01), None
patent: WO 9519369 (1995-07-01), None
patent: WO 9532311 (1995-11-01), None
patent: WO 9638463 (1996-12-01), None
patent: WO 9706256 (1997-02-01), None
patent: WO 9725426 (1997-07-01), None
patent: WO 9725431 (1997-07-01), None
patent: WO 9845328 (1998-10-01), None
patent: WO 0061753 (2000-10-01), None
Gencore, Amino acid database, Sequence 376 of U.S. Patent 6,329,505. Dec. 11, 2001.*
GenCore database sheet, nucleic acid and amino acid databases showing polypeptide from WO 9845328. Jan. 22, 1999.*
Ezzell, Carol. Cancer “vaccines”: an idea whose time has come? The Journal of NIH Research, 7:46-49, Jan. 1995.*
Adams et al., Genbank Accession No. Q60347, 1993.
Adams et al., Genbank Accession No. Q61250, 1993.
Anderson et al., “Sequence and organization of the human mitochondrial genome,”Nature 290:457-465, 1981.
Bauer et al., “Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR),”Nucleic Acids Research 21(18):4272-4280, 1993.
Bernard et al., “Cloning and Sequencing of Pro-α1(XI) Collagen cDNA Demonstrates That Type XI Belongs to the Fibrillar Class of Collagens and Reveals That the Expression of the Gene Is Not Restricted to Cartilagenous Tissue,”J. Biol. Chem. 263(32):17159-17166, 1988.
Bratthauer et al., “Expression of LINE-1 Retrotransposons in Human Breast Cancer,”Cancer 73:2333-2336, 1994.
Byrne et al., “A Screening Method to Identify Genes Commonly Overexpressed in Carcinomas and the Identification of a Novel Complementary DNA Sequence,”Cancer Research 55:2869-2903, 1995.
Chai et al., Genbank Accession No. U03644, 1994.
Charnock-Jones et al., “Extension of incomplete cDNAs (ESTs) by biotin/streptavidin-mediated walking using polymerase chain reaction,”J. Biotechno. 35:205-215, Jun. 1994.
Chen and Sager, “Differential Expression of Human Tissue Factor in Normal Mammary Epithelial Cells and in Carcinomas,”Molecular Medicine 1(2):153-160, 1995.
Cordonnier et al., “Isolation of Novel Human Endogenous Retrovirus-Like Elements with Foamy Virus-Related pol Sequence,”Journal of Virology 69(9):5890-5897, 1995.
Databank Genebank Accession No. Z34289, 1995.
Ezzell, “Cancer “Vaccines”: An Idea Whose Time Has Come?,”The Journal of NIH Research 7:46-49, 1995.
Frank et al., Genbank Accession No. Q70049, 1994.
Gura, “Systems for Identifying New Drugs Are Often Faulty,”Science 278:1041-1042, 1997.
Haltmeier et al., “Identification of S71-Related Human Endogenous Retroviral Sequences with Full-Length pol Genes,”Virology 209:550-560, 1995.
Hillier et al., Genbank Accession No. H80165, 1995.
Hillier et al., Genbank Accession No. R19532, 1995.
Hillier et al., Genbank Accession No. R55637, 1995.
Hillier et al., Genbank Accession No. R60426, 1995.
Hillier et al., Genbank Accession No. T83348, 1995.
Hillier et al., Genbank Accession No. R35308, 1995.
Keydar et al., “Properties of retrovirus-like particles produced by a human breast carcinoma cell line: Immunological relationship with mouse mammary tumor virus proteins,”Proc. Natl. Acad. Sci.USA 81:4188-92, 1984.
Leib-Mösch and Seifarth, “Evolution and Biological Significance of Human Retroelements,”Virus Genes 11(2/3):133-145, 1996.
Leib-Mösch et al., “Endogenous Retroviral Elements in Human DNA,”Cancer Research 50:5636s-5642s, 1994.
Leib-Mösch et al., “Genomic Distribution and Transcription of Solitary HERV-K LTRs,”Genomics 18:261-269, 1993.
Liang et al., “Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction,”Science 257:967-971, 1992.
Matsubara et al., Genbank Accession No. T24124, 1995.
Wang et al., “Detection of Mammary Tumor Virus ENV Gene-like Sequences in Human Breast Cancer,”Cancer Research 55:5173-5179, 1995.
Watson and Fleming, “Isolation of Differentially Expressed Sequence Tags from Human Breast Cancer,”Cancer Research 54(17):4598-4602, 1994.
Werner et al., “S71 Is a Phylogenetically Distinct Human Endogenous Retroviral Element with Structural and Sequence Homology to Simian Sarcoma Virus (SSV),”Virology 174:225-238, 1990.
Yoshioka et al., “Pro-α1(XI) Collagen. Structure Of The Amino-Terminal Propeptide And Expression Of The Gene In Tumor Cell Lines,”J. Biol. Chem. 265(11):6423-6426, 1990.
Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, Presentation of the Intellectual Property Committee of the Biotechnology Industry Organization at the Oct. 17, 1994, Hearing of the U.S. Patent and Trademark Office, San Diego, CA, published by the Biotechnology Industry Organization, Washington, D.C., pp. 75, 100-107.
Ahmed et al., “Characterization of a retrovirus isolated form normal mink cells co-cultivated with a dog mammary tumour,”J. Gen. Virol. 42:179-184, 1979.
Bakker et al., “Generation of antimelanoma cytotoxic T lymphocytes for healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vivo,”Cancer Research 55:5330-5334, Nov. 15, 1995.
Cease et al., “T cell clones specific for an amphipathic α-helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides,”Journal of Experimental Medicine 164:1779-1784, Nov. 1986.
Derks et al., “Synthesis of a viral protein with molecular weight of 30,000 (p30) by leukemic cells and antibodies cross-reacting with simian sarcoma virus p30 in serum of a chronic myeloid leukemia patient,”Cancer Research 42:681-686, Feb. 1982.
Hehlmann et al., “Detection and biochemical characterization of antigens in human leukemic sera that cross-react with primate C-type viral proteins (M 30,000)1,”Cancer Research 43:392-399, Jan. 1983.
Herbrink et al., “Detection of antibodies cross-reactive with type C RNA tumor viral p30 protein in human sera and exudate fluids,”Cancer Research 40:166-173, Jan. 1980.
Hopp, T., “Computer prediction of protein surface features and antigenic determinants,”Molecular Basis of CancerPart B: Macromolecular Recognition, Chemotherapy, and Immunology:367-377, 1985.
Jerabek et al., “Detection and immunochemical characterization of a primate type C retrovirus-related p30 protein in normal human placentas,”Proc. Natl. Acad. Sci. USA 81:6501-6505, Oct. 1984.
Kast et al., “Role of HLA-A motifs in identification of potential CTL epitopes in human papillmavirus type 16 E6 and E7 proteins,”J. Immunol. 152:3904-3912, 1994.
Kawakami et al., “Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltratin
Dillon Davin C.
Frudakis Tony N.
Misher Lynda E.
Reed Steven G.
Retter Marc W.
Corixa Corporation
Harris Alana M.
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for the treatment and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423039